{
    "paper_id": "2341493d5775ddc5686bd1d110f1cdb074cef1f3",
    "metadata": {
        "title": "Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343",
        "authors": [
            {
                "first": "Shrinivas",
                "middle": [],
                "last": "Rathod",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Arbind",
                "middle": [],
                "last": "Dubey",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Amitava",
                "middle": [],
                "last": "Chowdhury",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Bashir",
                "middle": [],
                "last": "Rcspi",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Rashmi",
                "middle": [],
                "last": "Bashir",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "",
                "middle": [],
                "last": "Koul",
                "suffix": "",
                "affiliation": {},
                "email": ""
            }
        ]
    },
    "abstract": [],
    "body_text": [
        {
            "text": "We are in the midst of an unprecedented crisis worldwide. Since its first reports in China on 31 st December 2019, it spread extensively across the globe. As of 4 th April 2020, over 1100,000 cases and over 60000 deaths are reported worldwide. 1 These numbers continue to rise exponentially and the healthcare system is strained to maximum. [15] [16] In these unusual times, the use of reduced fractions/hypofractionation regimens is strongly recommended. Pre COVID19 era, for various reasons, the use of hypofractionated, was highly variable across the world despite supportive data. There is enough data to practice this regimen safely for common cancer sites as prostate, breast, rectum, lung and even palliative situations. 7, 17, 18, 19, 20, 21, 22 The use of hypofractionated and ultra hypofractionated radiation could save potential 10-20 visits, thus lower the risk of infection and even mitigate the risk of treatment breaks and allow the radiation facilities with reduced manpower. With the expected resource and manpower constraints, this model is gaining popularity. 23 A clinical scenario where boost radiation adds minimal benefits to the outcomes is also another potential opportunity to reduce the number of fractions. [24] [25] Judicious resource allocation is paramount and hypofractionation regimens serve a vital purpose. We used this model and proposed thoracic cancer specific provincial consensus. 7 Prostate and breast cancer specific radiation guidelines were recently proposed. 16 ",
            "cite_spans": [
                {
                    "start": 341,
                    "end": 345,
                    "text": "[15]",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 346,
                    "end": 350,
                    "text": "[16]",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 731,
                    "end": 734,
                    "text": "17,",
                    "ref_id": "BIBREF5"
                },
                {
                    "start": 735,
                    "end": 738,
                    "text": "18,",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 739,
                    "end": 742,
                    "text": "19,",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 743,
                    "end": 746,
                    "text": "20,",
                    "ref_id": "BIBREF8"
                },
                {
                    "start": 747,
                    "end": 750,
                    "text": "21,",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 751,
                    "end": 753,
                    "text": "22",
                    "ref_id": "BIBREF10"
                },
                {
                    "start": 1079,
                    "end": 1081,
                    "text": "23",
                    "ref_id": "BIBREF11"
                },
                {
                    "start": 1235,
                    "end": 1239,
                    "text": "[24]",
                    "ref_id": "BIBREF12"
                },
                {
                    "start": 1240,
                    "end": 1244,
                    "text": "[25]",
                    "ref_id": "BIBREF13"
                },
                {
                    "start": 1504,
                    "end": 1506,
                    "text": "16",
                    "ref_id": "BIBREF4"
                }
            ],
            "ref_spans": [],
            "section": ""
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "ductal carcinoma in situ: Risk of IBTR With RT Delay in DCIS",
            "authors": [],
            "year": 2017,
            "venue": "Cancer",
            "volume": "124",
            "issn": "1",
            "pages": "46--54",
            "other_ids": {
                "DOI": [
                    "10.1002/cncr.30972"
                ]
            }
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Intervals Longer Than 20 Weeks From Breast-Conserving Surgery to Radiation Therapy Are Associated With Inferior Outcome for Women With Early-Stage Breast Cancer Who Are Not Receiving Chemotherapy",
            "authors": [
                {
                    "first": "I",
                    "middle": [
                        "A"
                    ],
                    "last": "Olivotto",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "L"
                    ],
                    "last": "Lesperance",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "T"
                    ],
                    "last": "Truong",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "J Clin Oncol",
            "volume": "27",
            "issn": "1",
            "pages": "16--23",
            "other_ids": {
                "DOI": [
                    "10.1200/jco.2008.18.1891"
                ]
            }
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Timing of radiotherapy and outcome in patients receiving adjuvant endocrine therapy",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Karlsson",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "F"
                    ],
                    "last": "Cole",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Colleoni",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Int J Radiat Oncol Biology Phys",
            "volume": "80",
            "issn": "2",
            "pages": "398--402",
            "other_ids": {
                "DOI": [
                    "10.1016/j.ijrobp.2010.02.042"
                ]
            }
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910",
            "authors": [
                {
                    "first": "T",
                    "middle": [
                        "M"
                    ],
                    "last": "Pisansky",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Hunt",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "G"
                    ],
                    "last": "Gomella",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Journal of Clinical Oncology",
            "volume": "33",
            "issn": "4",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Prostate Cancer Radiotherapy Recommendations in Response to COVID-19",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Zaorsky",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Yu",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Mcbride",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Advances in Radiation Oncology 2020",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Conventional versus hypofractionated highdose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, noninferiority, phase 3 CHHiP trial",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Dearnaley",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [],
                    "last": "Syndikus",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Mossop",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "The Lancet Oncology",
            "volume": "17",
            "issn": "8",
            "pages": "1047--1060",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RTPC randomised, non-inferiority, phase 3 trial. The Lancet",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Widmark",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Gunnlaugsson",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Beckman",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "",
            "volume": "394",
            "issn": "",
            "pages": "385--395",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "Acute skin toxicity associated with a 1-week the UK FAST-Forward Trial",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Brunt",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Wheatley",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Yarnold",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Radiother Oncol",
            "volume": "120",
            "issn": "",
            "pages": "114--118",
            "other_ids": {
                "DOI": [
                    "10.1016/j.radonc.2016.02.027"
                ]
            }
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial",
            "authors": [
                {
                    "first": "T",
                    "middle": [
                        "J"
                    ],
                    "last": "Whelan",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Julian",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "S"
                    ],
                    "last": "Berrang",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Lancet",
            "volume": "394",
            "issn": "19",
            "pages": "32515--32517",
            "other_ids": {
                "DOI": [
                    "10.1016/S0140-6736"
                ]
            }
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial",
            "authors": [
                {
                    "first": "F",
                    "middle": [
                        "A"
                    ],
                    "last": "Vicini",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "S"
                    ],
                    "last": "Cecchini",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "R"
                    ],
                    "last": "White",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Lancet",
            "volume": "394",
            "issn": "",
            "pages": "2155--64",
            "other_ids": {
                "DOI": [
                    "10.1016/S0140-6736(19)32514-0"
                ]
            }
        },
        "BIBREF10": {
            "ref_id": "b10",
            "title": "Quality of Life Outcomes in a Phase 3 Randomized Trial of Optimization of Treatment of Advanced Non-small Cell Lung Cancer Using Radiation Therapy and Chemotherapy: IAEA Multicentric Randomized Phase 3 Study (NCT00864331)",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Rathod",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Jb",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Fidarova",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "International Journal of Radiation Oncology \u2022 Biology \u2022 Physics",
            "volume": "99",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF11": {
            "ref_id": "b11",
            "title": "Adapting Radiotherapy Treatments for Breast Cancer Patients during the COVID-19 Pandemic: Hypofractionation and Accelerated Partial Breast Irradiation to Address World Health Organization Recommendations. Advances in Radiation Oncology 2020",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Al-Rashdan",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Roumeliotis",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Quirk",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF12": {
            "ref_id": "b12",
            "title": "Association of Radiotherapy Boost for Ductal Carcinoma In Situ With Local Control After Whole-Breast Radiotherapy",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "S"
                    ],
                    "last": "Moran",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Ma",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Jama Oncol",
            "volume": "3",
            "issn": "8",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1001/jamaoncol.2016.6948"
                ]
            }
        },
        "BIBREF13": {
            "ref_id": "b13",
            "title": "Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial",
            "authors": [
                {
                    "first": "H",
                    "middle": [],
                    "last": "Bartelink",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Maingon",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Poortmans",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Lancet Oncol",
            "volume": "16",
            "issn": "1",
            "pages": "47--56",
            "other_ids": {
                "DOI": [
                    "10.1016/s1470-2045(14)71156-8"
                ]
            }
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "Immunocompromised and elderly individuals are susceptible to COVID19 with a higher risk of mortality. 2 Data shows an aggressive course of COVID19 and over 3 times higher risk of death in cancer patients.3  The Healthcare system is under enormous pressure to deal with this constantly changing and ever-evolving crisis. Several countries and provinces are reallocating resources and prioritizing available options in this emergency.Radiation Oncology is an integral part of Cancer care and expected to face significant challenges in the coming weeks as COVID19 continues to impact our lives.4-6 Classical Radiation oncology is based on 4 classical Rs of repair, reassortment, repopulation and reoxygenation. In the COVID-19 pandemic and global emergency, we suggested 4 new R based radiation oncology model mitigate the impact of the current pandemic on our patients and cancer centers. 7 The new 4R's include [1] Remote / ViRtual care (reduce in-person consult / follow up / on treatment visits) [2] Ration radiation (offer radiation wisely and avoid RT where minimal benefit) [3] Rational defeRring of radiation (as appropriate) [4] Reduce fractions / hypofRactionate radiation (where applicable) Significant emphasis is placed on minimizing in-person visits for patients and several Canadian provinces adopted Remote / viRtual care as a standard model in the current emergency. 8 This will help minimize patient visits to the hospital and thus the risk of infection. Radiation Oncologists should wisely Ration radiation and avoid radiation in cases where there is a minimal or questionable benefit. Favourable Ductal carcinoma in situ 9 (mammographically detected, <2.5cm in size, low-intermediate grade, adequate resection margins), favourable lowgrade invasive breast carcinoma 10 (age 70 years and older, primary <=3cm with negative resection margins, estrogen receptor +, node-negative and eligible to receive endocrine therapy), low-volume favourable intermediate-risk prostate carcinoma 11 may be appropriate for active surveillance. There are several such potential scenarios where avoiding radiation should be strongly considered. We should also diligently assess options of Rational defeRring of radiation as appropriate based on the clinical scenario. Ductal carcinoma in situ and invasive breast carcinoma could be safely delayed up to 12 weeks. 12-14 Favourable intermediate-risk prostate cancer and unfavourable intermediate-risk prostate cancer could defer radiation for 3-4 months or longer. Androgen deprivation therapy could be used as a temporizing measure for radiation deferral in appropriate cases such as unfavourable intermediate-risk and highrisk prostate cancer.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF1": {
            "text": "framework could help the several other disease site group design and use site-specific policies. This would help global radiation oncology community use the constrained resources efficiently, function and fight better, and ultimately flatten the curve of COVID-19 pandemic. May we all emerge victoriously.",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "Shrinivas Rathod* FRCPC, Arbind Dubey* FRCPC, Amitava Chowdhury* RCSPI, Bashir Bashir* FRCPC, Rashmi Koul* FRCPC * CancerCare Manitoba and University of Manitoba, Winnipeg, Manitoba, Canada",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}